SHANGHAI, June 13, 2026 (The Eastern Herald) — Chinese biotechnology firms signed 53 outbound innovative-drug licensing deals in the first quarter of 2026, an unprecedented quarterly volume that delivered 3.3 billion United States dollars of upfront cash, more than 60 billion dollars of headline deal value and a Chinese-origin share of global pharmaceutical business-development activity that has now passed 50 percent for the first time in the modern era of the industry. The Pfizer-Innovent collaboration completed last year at 10.5 billion dollars and the Eli Lilly-Innovent oncology and immunology programme announced in February at 8.85 billion dollars have set the upper end of the new range. The US Biosecure Act, signed into law in December 2025 as part of the National Defense Authorization Act, has reshaped the deal structures but, six months in, has done very little to slow the volume.
The economics that drive the new licensing geometry are straightforward. Chinese biotech firms, which produce a meaningful share of the world’s new clinical-stage oncology, immunology and cardiometabolic assets at significantly lower research-and-development costs than their American or European counterparts, can monetise those assets through ex-China territory licensing deals while retaining the Chinese commercial rights. Multinational pharmaceutical groups, facing the steepest patent-cliff cycle in two decades and a sustained demand surge driven by GLP-1 obesity drugs, can refill their pipelines for a fraction of the cost of mid-stage acquisitions of Western biotech start-ups. The arrangement is mutually attractive enough that the deal volume has scaled fast.
Innovent Biologics has been the marquee deal-maker. The February 2026 Eli Lilly partnership covers a multi-asset oncology and immunology programme with 350 million dollars of upfront payments to Innovent and up to 8.5 billion dollars of milestone payments contingent on regulatory and commercial achievements across the United States, Europe and Japan. Innovent retains Chinese commercial rights to all of the included assets, and Eli Lilly takes global ex-China commercialisation responsibility. The structure is now the template that the rest of the Chinese biotech industry is replicating across deal sizes.
RemeGen’s deal with AbbVie, announced earlier this year, included 650 million dollars of upfront payments and up to 5.6 billion dollars of total potential consideration. CSPC reached a strategic cooperation framework with AstraZeneca that has been structured to a 18.5 billion dollar maximum value across multiple programmes and across multiple development milestones. Sino Biopharm, Hengrui Pharmaceutical, Junshi Biosciences and BeiGene have all closed materially smaller but directionally similar deals with Bristol-Myers Squibb, Merck, Roche, Sanofi and Pfizer. The cumulative picture is that the global pharmaceutical pipeline is now being substantially rebuilt around Chinese-origin clinical-stage assets.
The competitive cost structure that supports this volume is real and worth flagging. Chinese clinical-trial costs run roughly 30 to 40 percent of the equivalent United States costs on a per-patient-enrolled basis, and Chinese research-and-development overhead is roughly 50 percent of the United States equivalent. The combination produces assets that arrive at the Phase 2 readout stage with materially lower sunk costs than American or European biotechs spend to reach the same gate. The multinational pharmaceutical groups have responded to that arithmetic by treating Chinese biotech firms as outsourced pipeline-development partners rather than as competitors. GSK’s 10.6 billion dollar acquisition of Nuvalent earlier this month, which targeted a Boston-based lung-cancer specialist, is the alternative model that Western majors will increasingly find harder to compete with on cost.
The US Biosecure Act is the political obstacle that should, in theory, have constrained the deal flow. The legislation prohibits United States federal contracting with biotechnology companies operating on behalf of designated foreign-adversary governments and was specifically targeted at WuXi AppTec, WuXi Biologics, BGI Genomics, MGI Tech and Complete Genomics. The legislative intent was to restrict the Chinese-American biotech supply-chain interface across clinical-trial outsourcing, contract development and manufacturing and genomic services. The effect on the licensing deal flow has been almost nil. The deals being structured are intellectual-property assets rather than contract-services flows, and the Biosecure Act does not prohibit private-sector licensing of clinical-stage compounds.
What has changed is the documentation. Multinational deal teams are now requiring extensive representations and warranties that the Chinese counterparty is not subject to the Biosecure Act’s prohibitions, that the clinical data underlying any licensed compound was generated independent of restricted Chinese contract research organisations and that the future development pathway will not rely on restricted Chinese contract-manufacturing capacity. Those representations add cost and complexity to the deals but do not block them. The bigger Chinese biotech firms have responded by re-papering their internal compliance architecture and, in several cases, by selectively divesting equity stakes in subsidiaries that touch Biosecure-restricted activities.
The geopolitical signal is the part that travels furthest. The Pentagon’s addition of Alibaba, BYD and Baidu to its 1260H designated military companies list earlier this week, combined with the Biosecure Act and the broader semiconductor export-control architecture, has produced a United States policy posture that aims to slow Chinese technology transfer to the United States. The biotech industry has produced one of the clearest counter-examples to that posture. The deal flow continues, the deal sizes have grown, and the structural advantages that the Chinese sector brings to global pharmaceutical pipelines have only become more compelling as the patent-cliff cycle has hardened.
The Chinese capital-markets infrastructure is supporting the trend. CITIC Securities’ first A-category Fitch rating, the Hong Kong fund-manager carry-tax bill and the broader IPO-market reopening for Chinese hard-tech issuers all reinforce the financial-architecture support for the next generation of Chinese biotech companies. Wuxi-listed BeiGene’s share-price recovery this year, Innovent’s Hong Kong-listed performance and the broader Hang Seng Biotech Index moves are all aligned with the licensing-deal flow that the sector is generating. The cumulative effect is a Chinese biotech sector that is increasingly self-financing the next clinical-stage pipeline and increasingly exporting that pipeline through licensing deals.
The American biotech sector is reading the trend with growing alarm. United States-listed Boston-area biotech indices have been outperforming since the start of the year on the assumption that Chinese-origin asset competition will accelerate the consolidation of the smaller American biotechs, but the equity-research community has begun to highlight the longer-running risk that Chinese-origin assets reduce the addressable market for early-stage American biotech equity. The Boston, Cambridge and Bay Area venture-capital communities have been quietly reducing their early-stage exposure to American clinical-stage start-ups and increasing their Chinese-clinical-asset exposure through Hong Kong-listed proxies. That capital rotation is the bull case for the sector that the licensing data has been telling investors about for several quarters.
The pharmaceutical industry’s response has been more pragmatic than the political environment suggests. Pfizer’s chief executive Bourla, Eli Lilly’s chief executive David Ricks, AstraZeneca’s Pascal Soriot and AbbVie’s Robert Michael have all been clear in investor calls that Chinese-origin licensing is now a permanent and growing component of their pipeline strategies. The implicit endorsement is that the Biosecure Act’s specific exclusions cover the contract-services interface but do not cover the intellectual-property licensing interface, and that the latter is where the deal value is increasingly concentrated.
The risk environment is meaningfully more difficult than the deal flow implies. The political pressure on Chinese biotech could escalate under a Trump-administration policy review that has been actively considering further restrictions, including a possible extension of the Biosecure Act to private-sector commercial licensing rather than only federal contracting. The Chinese clinical-trial regulatory environment is itself subject to political volatility, and the Center for Drug Evaluation in Beijing has been processing higher-than-usual application volumes that could produce regulatory delays. The litigation risk around intellectual-property origin is also rising as American biotechs increasingly challenge the patent priority of Chinese-origin assets in United States and European courts.
None of those risks has materially slowed the deal flow in the first half of 2026. The fundamental economics that drive the licensing arrangement, including the cost advantage of Chinese clinical development, the patent-cliff pressure on Western pharmaceutical pipelines and the structural attractiveness of the ex-China deal structure to both sides, are robust enough to absorb most of the headline political risk. The South China Morning Post framed the Chinese biotech industry’s positioning as global expansion that is irreversible despite US barriers. The Wire China’s earlier reporting sets out the structural backdrop.
The cleanest read of the trend is structural. Chinese biotech firms have built a clinical-stage pipeline at lower cost than their Western competitors, and the multinational pharmaceutical groups have recognised that licensing those assets is more economic than acquiring American or European biotechs at the same stage. The Biosecure Act has shaped the legal architecture around the deals but has not altered the economic logic. The 60 billion dollar Q1 deal volume is therefore not a peak. It is a floor for what the rest of the decade is likely to look like as the patent-cliff cycle plays out and the Chinese clinical-stage pipeline continues to scale.
